经鼻高流量氧疗在I型呼吸衰竭和二氧化碳潴留不明显的Ⅱ型呼吸衰竭中的疗效

Abstract
Figure/Table
References (29)
Related Citation (15)

Download: PDF (621 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the curative effect of intranasal high flow oxygen therapy for type Ⅰ failure and Ⅱ respiratory failure with no obvious carbon dioxide retention. Methods A total of 60 patients with type Ⅰ failure and Ⅱ respiratory failure with no obvious carbon dioxide retention were selected as the research subjects from July 2019 to March 2020 in the Department of Respiratory Medicine of the Changshu NO.2 People’s Hospital, Jiangsu Province, according to numerical odd-even method, they were divided into control group and observation group, with 30 cases in each group. The control group was treated with non-invasive positive pressure ventilation, and the observation group was treated with transnasal high-flow oxygen therapy. The effective rate of treatment was compared between the two groups, blood gas analysis indexes, hemodynamic indexes, comfort score and Borg score were recorded before and after treatment, and the incidence of adverse events during treatment was observed between the two groups. Results The total effective rate of observation group was higher than control group, and the difference was statistically significant (P ＜ 0.05). After treatment, the levels of oxygen saturation (SpO2) and oxygen partial pressure (SaO2) in the two groups were significantly higher than before treatment, the level of carbon dioxide partial pressure (PaCO2) was lower than before treatment, and after treatment, the levels of PaO2 and SaO2 in the observation group were higher than the control group, while the levels of PaCO2 was lower than the control group, with statistical significance (P ＜ 0.05). After treatment, heart rate (HR), respiratory rate (RR) and pulmonary artery pressure (PAP) in the two groups were lower than before theatment, and the observation group was lower than the control group, the differences were statistically significant (P ＜ 0.05). After treatment, the comfort scores of the two groups were higher than before treatment, the Borg scores were lower than before treatment, and the comfort score of the observation group was higher than the control group, and the Borg score was lower than the control group, and the differences were statistically significant (P ＜ 0.05). The incidence of adverse events in observation group was lower than that in control group, and the difference was statistically significant (P ＜ 0.05). Conclusion Transnasal high-flow oxygen therapy can significantly improve the clinical symptoms and oxygen status for typeⅠfailure and Ⅱ respiratory failure with no obvious carbon dioxide retention, and improve the comfort level and reduce the occurrence of adverse events.

Key words： High flow oxygen therapy TypeⅠrespiratory failure Type Ⅱ respiratory failure Clinical efficacy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YOU Zhenhua HUANG Jinhong ZHAO Yungen GU Yuping

Cite this article:

YOU Zhenhua HUANG Jinhong ZHAO Yungen GU Yuping. Efficacy of intranasal high flow oxygen therapy for type Ⅰ respiratory failure and type Ⅱ respiratory failure with no obvious carbon dioxide retention[J]. 中国医药导报, 2021, 18(16): 82-85,90.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I16/82

[1] 喻正浩，张瑞，黄卉，等.经鼻高流量湿化氧疗应用于慢性阻塞性肺疾病合并2型呼吸衰竭患者气管插管拔管后的疗效和安全性：随机对照研究[J].第二军医大学学报，2019，40（9）：697-700.
[2] 赵慧颖，罗建，吕杰，等.外科ICU患者脱机后序贯经鼻高流量氧疗的特点及治疗失败的危险因素分析[J].中华危重病急救医学，2019，31（6）：689-693.
[3] 刘景刚，杨圣强，袁继印，等.经鼻高流量氧疗序贯治疗慢性阻塞性肺疾病机械通气患者的临床研究[J].中华急诊医学杂志，2019，28（4）：459-462.
[4] 李建生，王至婉，余学庆，等.慢性阻塞性肺疾病急性加重期证候诊断标准的建立[J].中华中医药杂志，2010，24（7）：971-975.
[5] 郭仓.呼吸衰竭的表现、诊断标准及防治原则[J].中华危重病急救医学，1996，7（1）：37.
[6] 王可，徐思成，左蕾，等.经鼻高流量吸氧治疗急性呼吸衰竭的系统评价[J].中华急诊医学杂志，2017，26（8）：879-884.
[7] 刘广杰，刘志，刘刚，等.间质性肺疾病患者呼吸困难的定量评价研究[J].中国医科大学学报，2001，30（2）：152.
[8] 麦雪萍，王磊.BORG主观体力感等级量表的生理效度研究：一项元分析[J].广州体育学院学报，2012，32（3）：78-83.
[9] 邓玎玎，周爱媛，双庆翠，等.呼出气一氧化氮测定对支气管哮喘-慢性阻塞性肺疾病重叠综合征的诊断价值[J].中华结核和呼吸杂志，2017，40（2）：98-101.
[10] Papi A，Vestbo J，Fabbri L，et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease （TRIBUTE）：A double-blind，parallel group，randomised controlled trial [J]. Lancet，2018，391（10125）：1076.
[11] 肖贤富.NPPV联合雾化吸入治疗老年COPD肺部感染合并Ⅱ型呼吸衰竭的临床效果观察[J].中国当代医药，2019，26（12）：101-103.
[12] 潘建伽，罗书裕.经鼻高流量氧疗对呼吸衰竭的效果观察[J].中国当代医药，2019，26（6）：51-53.
[13] 戈艳蕾，刘聪辉，张嘉宾，等.慢性阻塞性肺疾病伴或不伴低氧血症患者外周血MCP-1、SAA蛋白及mRNA水平与认知功能损伤关系探讨[J].中国呼吸与危重监护杂志，2018，17（4）：5481-5483.
[14] 高健婷，王秋雁.早期接受不同剂量肠内营养对急性呼吸衰竭患者预后的影响[J].中华危重病急救医学，2017， 29（11）：1010-1014.
[15] Liu CY，Parikh M，Bluemke DA，et al. Pulmonary artery stiffness in chronic obstructive pulmonary disease （COPD） and emphysema：The Multi-Ethnic Study of Atherosclerosis （MESA） COPD Study [J]. J Magn Reson Imaging，2018，47（1）：262.
[16] 程诺，赵月，王爱平.经鼻高流量氧疗对慢性阻塞性肺疾病急性加重伴Ⅱ型呼吸衰竭患者有效性及安全性的Meta分析[J].中国实用护理杂志，2020，36（35）：2794-2801.
[17] 周璐，孙永昌.慢性阻塞性肺疾病肺淋巴组织新生的意义和发生机制研究进展[J].中华结核和呼吸杂志，2019，42（4）：286-289.
[18] 冯晓东，张贵良，曾利华，等.经鼻高流量氧疗治疗急性呼吸衰竭的随机对照试验[J].中国呼吸与危重监护杂志，2020，19（5）：71-76.
[19] Wen W，Yu G，Liu W，et al. Silencing FUNDC1 alleviates chronic obstructive pulmonary disease by inhibiting mitochondrial autophagy and bronchial epithelium cell apoptosis under hypoxic environment [J]. J Cell Biochem，2019，120（10）：17602-17615.
[20] 林锦胡，王君宇，陈风华，等.中高流量颅内-外血管搭桥术治疗复杂性颅内动脉瘤的疗效及桥血管的选择研究[J].中华神经医学杂志，2019，18（2）：144-149.
[21] 张毅斐，武元赫，杨萍.经鼻高流量氧疗治疗超高龄急性低氧性呼吸衰竭患者的临床研究[J].中国现代医生，2020，58（30）：108-111.
[22] 沈莉荣，杨祖铭，王三南，等. 早产儿肺出血拔管后序贯加温、加湿高流量鼻导管吸氧的疗效[J].中华实用儿科临床杂志，2019，34（18）：1382-1385.
[23] 黄桃，何发明，郭睿，等.经鼻高流量湿化氧吸入疗法对急性低氧性呼吸衰竭的疗效研究[J].重庆医学，2016， 45（34）：4769-4771.
[24] 戴喜明，高青豹，胡清甫.醒脑静注射液联合床旁高流量持续血液净化治疗脓毒性休克48例临床分析[J].重庆医学，2016，45（14）：1978-1980.
[25] 黄琳娜，李正东，夏金根，等.经鼻高流量氧疗在急性呼吸衰竭治疗中的应用[J].中华结核和呼吸杂志，2019， 42（1）：41.
[26] 王健，马新华，李莉，等.经鼻高流量氧疗治疗Ⅰ型呼吸衰竭的疗效分析[J].中国现代医学杂志，2018，28（14）：65-70.
[27] 李琦，刘双林，刘刚.经鼻高流量氧疗与无创正压通气的合理应用[J].中华结核和呼吸杂志，2020，43（9）：733-736.
[28] 左利平，俞树青，刘洪艳，等.经鼻高流量氧疗在急性呼吸衰竭患者急诊救治中的应用[J].中国现代医生，2019， 57（17）：4-7.
[29] 李钧.经鼻高流量氧疗在AECOPD伴Ⅱ型呼吸衰竭患者中的应用及其实施效果[J].中国医学创新，2020，17（9）：9-13.